title: Erythrocyte phosphoglucomutase activity of bipolar I patients currently using lithium or carbamazepine.
abstract: Lithium has been used for the last five decades to treat bipolar disorder, but the molecular basis of its therapeutic effect is unknown. Phosphoglucomutase is a key enzyme in the metabolism of glycogen. In yeast, rabbit and human HEK293 cells, it is inhibited by lithium in the therapeutic concentration range. We measured the phosphoglucomutase activity in erythrocytes and the inhibitor constant for lithium in a population of healthy subjects and compared them to those of bipolar patients treated with lithium or carbamazepine. The specific activity of phosphoglucomutase measured in vitro in erythrocytes from control subjects presented a normal distribution, with the difference between the lowest and the highest activity being approximately 2-fold (0.53-1.10 nmol mg Hb-1 min-1). Comparison of phosphoglucomutase activity in untreated bipolar patients and control subjects showed no significant difference, whereas comparison between bipolar patients treated with carbamazepine or lithium revealed significantly lower mean values in patients treated with carbamazepine (747.3 +/- 27.6 vs 879.5 +/- 35.9 pmol mg Hb-1 min-1, respectively). When we studied the concentration of lithium needed to inhibit phosphoglucomutase activity by 50%, a bimodal distribution among the population tested was obtained. The concentration of LiCl needed to inhibit phosphoglucomutase activity by 50% was 0.35 to 1.8 mM in one group of subjects and in the other it was 3 to 4 mM. These results suggest that phosphoglucomutase activity may be significant in patients with bipolar disorder treated with lithium and carbamazepine.
authors.affiliation: Programa de Biologia Molecular e Biotecnologia, Instituto de Bioquímica Médica, Universidade Federal do Rio de Janeiro, Brasil. montero@bioqmed.ufrj.br
authors.forename: M
authors.initials: M
authors.lastname: Montero-Lomelí
authors.forename: D
authors.initials: D
authors.lastname: Galvão
authors.forename: B B
authors.initials: BB
authors.lastname: Morais
authors.forename: A E
authors.initials: AE
authors.lastname: Nardi
mesh_terms: D000293:Adolescent; D000328:Adult; D018692:Antimanic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000201:enzymology; D010054:Brief Psychiatric Rating Scale; D002220:Carbamazepine / Q000494:pharmacology / Q000627:therapeutic use*; D016022:Case-Control Studies; D004912:Erythrocytes / Q000201:enzymology*; D005260:Female; D006801:Humans; D018020:Lithium Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010733:Phosphoglucomutase / Q000378:metabolism*
chemical_list: D018692:Antimanic Agents; D018020:Lithium Compounds; D002220:Carbamazepine; D010733:Phosphoglucomutase